Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozoralizumab - Ablynx/Eddingpharm/Taisho Pharmaceutical

Next Previous
Drug Profile

Ozoralizumab - Ablynx/Eddingpharm/Taisho Pharmaceutical

Alternative Names: anti-TNFα Nanobody®; ATN-103; Nanozora; Nanozora® 30mg Autoinjector; Ozoralizumab autoinjector; PF-5230896; TS-152

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ablynx
  • Developer Ablynx; Eddingpharm; Pfizer; Taisho Pharmaceutical
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Proteins
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Discontinued Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis

Most Recent Events

  • 28 Jul 2023 Ozoralizumab autoinjector (Nanozora® 30mg Autoinjector) approved for Rheumatoid arthritis in Japan
  • 28 Apr 2023 Taisho Pharmaceutical completes a phase III trial in Rheumatoid arthritis in Japan (SC) (NCT04077567)
  • 01 Dec 2022 Launched for Rheumatoid arthritis in Japan (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top